Pharm'Up 
Investment Overview
On July 24, 2025, a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) announced a significant investment of USD 200 million to acquire approximately 3% equity stake in Micro Life Sciences Private Limited (Meril), a leading Indian medical devices company. This transaction values Meril at an enterprise value of USD 6.6 billion. The deal is currently subject to approval by the Competition Commission of India (CCI), with expectations of completion pending regulatory clearance.
Company Profiles
About Meril
Meril, founded by the Bilakhia Group, is a globally recognized innovator in the medical technology (MedTech) sector. The company specializes in developing clinically advanced solutions across a broad spectrum of medical fields, including:
- Cardiovascular: Devices for heart-related treatments.
- Structural Heart: Innovative solutions for heart structure repairs.
- Orthopaedics: Advanced implants and surgical tools.
- Endo-Surgery: Minimally invasive surgical technologies.
- In-Vitro Diagnostics: Cutting-edge diagnostic tools.
- Surgical Robotics: State-of-the-art robotic-assisted surgery systems.
With a strong presence in India and expanding global reach, Meril continues to drive innovation in healthcare technology.
About ADIA
Established in 1976, the Abu Dhabi Investment Authority (ADIA) is a globally diversified investment institution responsible for managing the Government of Abu Dhabi’s surplus funds. ADIA employs a prudent, long-term investment strategy aimed at creating sustainable value. Its portfolio spans various asset classes worldwide, reflecting its commitment to financial stability and growth.
Transaction Details
- Investment Amount: USD 200 million.
- Stake Acquired: Approximately 3%.
- Valuation: USD 6.6 billion (enterprise value).
- Regulatory Status: Pending approval from the Competition Commission of India (CCI).
- Announcement Date: July 24, 2025.
This investment underscores ADIA’s confidence in Meril’s growth potential and the expanding MedTech market in India. The funds are expected to support Meril’s research and development efforts, global expansion, and innovation in medical device manufacturing.
Strategic Importance
The partnership between ADIA and Meril highlights the growing international interest in India’s healthcare and technology sectors. Meril’s expertise in advanced medical devices aligns with ADIA’s focus on long-term, high-value investments. This collaboration is poised to enhance Meril’s capabilities, potentially accelerating the development of next-generation medical technologies and improving healthcare outcomes globally.
Conclusion
The USD 200 million investment by ADIA in Meril marks a significant milestone for India’s MedTech industry. With regulatory approval, this deal could pave the way for further innovations and strengthen Meril’s position as a global leader in medical technology. ADIA’s involvement reflects a strategic move to capitalize on the burgeoning opportunities in the healthcare sector, promising a future of enhanced medical solutions.
Source Verification
Information is based on the official announcement dated July 24, 2025, and aligns with ADIA’s investment strategy and Meril’s industry standing as reported by credible financial and healthcare news outlets.
About the Author
Pharm'Up 
